OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED RENAL CANCER

Chairs
Toni K. Choueiri, Boston, MA, USA
Thomas B. Powles, London, UK

SATURDAY, 21 OCTOBER 2023
18:30 - 20:00 CEST, HALL 3 - SALAMANCA AUDITORIUM

| 18:30 | Welcome and introduction | Toni K. Choueiri  
Boston, MA, USA |
| 18:40 | Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma (RCC) | Viktor Grünwald  
Essen, Germany |
| 18:55 | State-of-the-art combination therapies for patients with advanced RCC | Laurence Albiges  
Villejuif, France |
| 19:10 | Do all patients need combination therapy? De-escalation and patient selection | Thomas B. Powles  
London, UK |
| 19:25 | Research insights in enhancing treatment efficacy: Escalation, sequencing and prediction | Toni K. Choueiri  
Boston, MA, USA |
| 19:40 | Q&A and discussion | All speakers |
| 19:55 | Concluding remarks | Thomas B. Powles  
London, UK |

This educational activity is provided by ESMO and supported by an unrestricted educational grant from Eisai.